Navigation Links
Inverness Medical Innovations Offers to Acquire Standard Diagnostics
Date:1/11/2010

WALTHAM, Mass., Jan. 11 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, announced today that it has commenced a cash tender offer to acquire a majority equity interest in Standard Diagnostics ("SD"), a leading innovator of rapid diagnostics in Korea.

Inverness has offered to acquire up to 75.79% of the issued shares of SD, and Dr. Young Shik Cho, Representative Director, President and CEO of SD and its largest shareholder, announced he will tender 720,000 of his own shares in support of Inverness' investment. Inverness' obligation to purchase shares is, amongst other things, conditioned on the tender of at least 2,408,000 shares (inclusive of Dr. Cho's 720,000), which is approximately 30.1% of the total shares issued as of January 8, 2010. If the minimum tender is achieved, Dr. Cho and IMI will collectively own more than 50% of SD.

The tender offer price is KRW 40,000, which represents a premium of over 33% of the 90-day trailing average (29,867 KRW) of SD's share price. Shareholders may tender their shares from January 11, 2010 until February 1, 2010. The settlement date is February 8, 2010.

Dr. Cho stated, "This proposed transaction provides SD with the resources and support to continue its growth as a globally competitive leader in the field of disease diagnosis." Upon successful completion of the tender offer, Dr. Cho would remain the President and CEO of SD.

"We look forward to working with Dr. Cho and his entire team at Standard Diagnostics," said Ron Zwanziger, President and CEO of Inverness. "Inverness is committed to providing products and service to enable patients to take charge of their own health at home. Our vision for improving patient outcomes aligns closely with the vision of Dr. Cho and SD. We are excited about the opportunity to partner with Dr. Cho and continue to expand our global presence."

About Inverness Medical Innovations

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life at home. Inverness' global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

About Standard Diagnostics

Standard Diagnostics, Inc., listed on the KOSDAQ stock market since January 23, 2003, is a global player in the medical diagnostics' industry. Its main products lines relate to diagnostics reagents or devices for hepatitis, infectious diseases, tumor markers, fertility, drugs of abuse, urine strips and protein strips. For more information on Standard Diagnostics visit www.standardia.com.

Cautionary Note Regarding Forward-Looking Statements:

This press release may contain forward-looking statements within the meaning of the United States federal securities laws, including statements regarding potential benefits and other results or effects of the tender offer. These statements reflect Inverness' current views with respect to future events and are based on management's current assumptions and information currently available. Actual results may differ materially due to numerous factors including, without limitation, increases in the price of SD shares, the possibility that no shares may be tendered, the possibility that conditions to the offer will not be satisfied, including the minimum share condition, the possibility of a competing offer, and the possibility that the anticipated benefits, including synergies, of the transaction will not be realized. Inverness undertakes no obligation to update any forward-looking statements.

SOURCE Inverness Medical Innovations, Inc.

RELATED LINKS
http://www.invernessmedical.com

'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Inverness Medical Innovations to Present at the J.P. Morgan Healthcare Conference on January 12, 2010
2. Inverness Medical Innovations Announces Third Quarter 2009 Results
3. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
4. Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General
5. Inverness Medical Innovations Receives USDA Licensure of the BinaxNOW(R) Avian Influenza Virus Type A Antigen Test Kit
6. Inverness Medical Innovations to Present at CIBC World Markets 18th Annual Healthcare Conference on November 7, 2007
7. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
8. Salt Lake City Medical Research Center Tests New Drug To Treat Painful Menstrual Cramps
9. Colorado-Based Spectranetics Corporation to Pay $5 Million to Resolve Allegations Relating to its Medical Devices
10. ViVre Medical Announces $6,000,000 Gift
11. University of Pittsburgh Medical Center (UPMC) Treats 10,000th Patient with Leksell Gamma Knife Radiosurgery System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... , ... Only two months after the official release of The Private Collection ... XO Private has initiated a second print-run of its lavish luxury travel coffee table ... when open, weighs in at more than six kilos, retails at EUR 1,000 per ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... In the ... to be a top priority because it’s not if you will be attacked, but ... especially when it comes to digital health care. , Improvements in auditing and monitoring ...
(Date:2/24/2017)... ... ... The California State University Institute for Palliative Care is pleased ... palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing Academic Palliative ... Sept. 28 and 29, 2017, on the campus of California State University San Marcos. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, a national ... , media relations, social media, content marketing and SEO, is now offering direct, ... an intuitive marketing automation platform. , Rosica will now offer the platform to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
Breaking Medicine News(10 mins):